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Abstract
The biosynthesis of eukaryotic lipid-linked oligosaccharides (LLOs) that act as donor substrates in
eukaryotic protein N-glycosylation starts on the cytoplasmic side of the endoplasmic reticulum
and includes the sequential addition of ﬁve mannose units to dolichol-pyrophosphate-GlcNAc2.
These reactions are catalyzed by the Alg1, Alg2 and Alg11 gene products and yield Dol-PP-
GlcNAc2Man5, an LLO intermediate that is subsequently ﬂipped to the lumen of the endoplasmic
reticulum. While the puriﬁcation of active Alg1 has previously been described, Alg11 and Alg2
have been mostly studied in vivo. We here describe the expression and puriﬁcation of functional,
full length Alg2 protein. Along with the puriﬁed soluble domains Alg1 and Alg11, we used Alg2 to
chemo-enzymatically generate Dol-PP-GlcNAc2Man5 analogs starting from synthetic LLOs contain-
ing a chitobiose moiety coupled to oligoprenyl carriers of distinct lengths (C10, C15, C20 and C25).
We found that while the addition of the ﬁrst mannose unit by Alg1 was successful with all of the
LLO molecules, the Alg2-catalyzed reaction was only efﬁcient if the acceptor LLOs contained a suf-
ﬁciently long lipid tail of four or ﬁve isoprenyl units (C20 and C25). Following conversion with
Alg11, the resulting C20 or C25 -containing GlcNAc2Man5 LLO analogs were successfully used as
donor substrates of puriﬁed single-subunit oligosaccharyltransferase STT3A from Trypanosoma
brucei. Our results provide a chemo-enzymatic method for the generation of eukaryotic LLO ana-
logs and are the basis of subsequent mechanistic studies of the enigmatic Alg2 reaction
mechanism.
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Introduction
During protein N-glycosylation, glycans from lipid-linked oligosac-
charides (LLOs) are transferred onto asparagine residues located in
N-glycosylation sequons (Breitling and Aebi 2013). In eukaryotes,
the transferred glycan contains the conserved core GlcNAc2Man5,
while a higher diversity in the chemical structure of the glycans is
observed in bacteria and archaea (Dell et al. 2010; Nothaft and
Szymanski 2010; Jarrell et al. 2014). In eukaryotes, the synthesis of
© The Author 2017. Published by Oxford University Press. 726
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
Downloaded from https://academic.oup.com/glycob/article-abstract/27/8/726/3859201
by Universitaetsbibliothek Bern user
on 18 December 2017
LLO comprises three steps: It begins with the biosynthesis of the
intermediate Dol-PP-GlcNAc2Man5, which occurs on the cytoplas-
mic side of the endoplasmic reticulum (ER). The second step is the
ﬂipping of this intermediate to the luminal side of the ER. The third
step comprises the glycan extension in the ER lumen, yielding Dol-
PP-GlcNAc2Man9 (Man9). In most eukaryotes, there is an addition
of three glucose units to generate Dol-PP-GlcNAc2Man5Glc3 (Aebi
2013).
The topic of this study is the biosynthesis of Dol-PP-GlcNAc2Man5,
which starts in the cytoplasm with the addition of N-acetylglucosamine-
phosphate (GlcNAc-P) to the phosphorylated lipid carrier dolichol
(Dol-P) by the GlcNAc-P transferase, Alg7 (Kukuruzinska et al.
1994). The second GlcNAc unit is added by the Alg13/14 complex,
generating Dol-PP-GlcNAc2 (Gao et al. 2008; Lu et al. 2012).
Subsequently, ﬁve mannose residues are added by the Alg1, Alg2 and
Alg11 proteins, proposed to form a complex in the ER membrane
(Gao et al. 2004). Alg1 adds a single mannose forming a β-1,4 glyco-
sidic bond (Couto et al. 1984). Alg2 produces the ﬁrst branch in the
core glycan of the eukaryotic N-glycosylation LLO by adding two
mannose units to the β-linked mannose added by Alg1, generating α-
1,3 and α-1,6 glycosidic linkages (Yamazaki et al. 1998; Takeuchi
et al. 1999; Kämpf et al. 2009). The intriguing dual-speciﬁcity reac-
tion mechanism of Alg2 is not understood to date, which is in part
due to the difﬁculties associated with the puriﬁcation of labile mem-
brane proteins such as Alg2 as well as the lack of sufﬁcient amounts
of lipid-linked GlcNAc2Man substrate needed to perform detailed
kinetic analyses. The cytoplasmic biosynthesis of the LLO is termi-
nated by the action of Alg11 that catalyzes the addition of two α1,2-
linked mannoses to the 1,3-linked mannose added by Alg2 (Cipollo
et al. 2001; O’Reilly et al. 2006; Absmanner et al. 2010). After trans-
location of Dol-PP-GlcNAc2Man5, further extension of the oligosac-
charide is carried out in the lumen of the ER where Dol-P-Man and
Dol-P-Glc, respectively, act as substrates for membrane-embedded
glycosyltransferases (Burda and Aebi 1999).
In Trypanosoma brucei, luminal biosynthesis proceeds to the
Dol-PP-GlcNAc2Man9 stage, but either lipid-linked GlcNAc2Man5
or GlcNAc2Man9 glycans are used as substrates in protein
N-glycosylation, catalyzed preferentially by the single-subunit OST
enzymes TbSTT3A or TbSTT3B, respectively (Manthri et al. 2008;
Izquierdo et al. 2009, 2012). This substrate preference has only been
studied in vivo, the unavailability of sufﬁcient amounts of pure
LLOs has prevented detailed kinetic studies. We have previously
reported the expression and puriﬁcation of TbSTT3A as well as its
characterization with LLO analogs composed by chitobiose coupled
to oligoprenyl carriers of different lengths (Ramírez et al. 2017).
Here, we describe the preparation of LLO analogs with elongated
glycan moieties by biochemical addition of mannose units using
recombinantly expressed and puriﬁed Alg1, Alg2 and Alg11, in ana-
logy to the early steps of the biosynthesis of the eukaryotic native
LLO. The generated LLO analogs were fully functional substrates
for puriﬁed TbSTT3A in in vitro glycosylation assays.
Results
Expression and puriﬁcation of CT-Alg1, Alg2 and
CT-Alg11
In vitro preparation of a dolichol-linked GlcNAc2Man5 LLO had pre-
viously been performed by reaction of Dol-PP-GlcNAc2 with Alg1
expressed and puriﬁed from yeast and with membranes from
Escherichia coli expressing full length Alg2 and Alg11 (O’Reilly et al.
2006). However, neither the Alg2 and Alg11 enzymes nor the result-
ing GlcNAc2Man5-containing LLO had been puriﬁed for that study.
For our structural and functional investigations of the Alg pathway as
Fig. 1. (A) Schematic of chemo-enzymatic synthesis strategy to extend the glycan moiety of synthetic LLO analogs to Dol-PP-GlcNAc2Man5. Alg1Cyto refers to
His10-zz-TEV-Alg1(aa 33–349); Alg2 refers to His10-YFP-3C-Alg2 and Alg11Cyto refers to His10-zz-TEV-Alg11(aa 46–548). (B) SDS–PAGE analysis of the puriﬁed
Alg1Cyto (lane 1), Alg2 (lane 2) and Alg11Cyto (lane 3). MW refers to marker proteins, with molecular masses indicted on the side. The asterisk depicts an impurity
that co-eluted during Alg2 puriﬁcation. This ﬁgure is available in black and white in print and in color at Glycobiology online.
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well as for bioengineering purposes, working with the native dolichol
is challenging due to the low solubility and the limited amounts that
can be generated or obtained. Additionally, working with membrane
preparations instead of puriﬁed proteins necessitates more and chal-
lenging puriﬁcation steps of the reaction products (GlcNAc2Man5-
LLOs). To overcome these difﬁculties, we expressed and puriﬁed
active Alg1, Alg2 and Alg11 proteins, which were used to sequentially
add ﬁve mannose units to synthetic LLOs bearing a chitobiose moiety
coupled to polyprenyl tails of different length (Figure 1A).
The topologies of the yeast Alg1 and Alg11 membrane proteins
are similar. Both proteins contain a single, N-terminal transmembrane
helix followed by a cytoplasmic, C-terminal domain that harbors the
catalytic activity. It was shown earlier that cell extracts of E. coli
expressing only the cytoplasmic domain of Alg1 could add one man-
nose residue to Dol-PP-GlcNAc2 in vitro (Couto et al. 1984). Based
on these ﬁndings, we expressed and puriﬁed the cytoplasmic domain
of Alg1 (Alg1Cyto, aa 33–349) and Alg11 (Alg11Cyto, aa 46–548),
both fused to a His10-zz-TEV tag to their N-terminus. Both domains
showed to be strongly associated with the cell membrane of E. coli,
and could only be extracted after incubation with detergent (0.5%
Triton X-100). These observations agreed with a previous report sug-
gesting that the soluble domain of Alg11 contains two hydrophobic
or amphipathic helices in addition to its transmembrane helix,
strengthening its association with the ER membrane (Absmanner
et al. 2010). We succeeded in purifying both proteins, although
sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS–
PAGE) analysis of Alg11 showed additional bands corresponding to
degradation products as conﬁrmed by mass spectrometry (MS) ana-
lysis (data not shown). However, these did not negatively affect the
catalytic activity of Alg11 (Figure 1B).
The yeast Alg2 protein has a very different topology compared
to Alg1 or Alg11. Alg2 consists of two transmembrane helices at the
Fig. 2. (A) Schematic of product analysis of the Alg protein reactions. The glycans from chemo-enzymatically generated LLO analogs were transferred onto the
ﬂuorescently labeled peptide 5CF-GSDANYTYTQ by in vitro glycosylation using puriﬁed TbSTT3A protein. Glycopeptides were subsequently analyzed by
Tricine SDS–PAGE and LC–MS/MS. (B) Tricine SDS–PAGE analysis of glycopeptides produced from LLO analogs with different lipid tails after processing with
Alg1Cyto, Alg2 and Alg11Cyto. (1) (S)-Citronellyl, C10; (2) Farnesyl, C15; (3) (S)-NerylCitronellyl, C20; (4) (S)-FarnesylCitronellyl, C25. *Reaction with Alg11 was not
performed for the LLOs containing lipids 1 and 2 because the preceding reaction with Alg2 was not successful. LC–MS/MS, liquid chromatography–tandem
mass spectrometry. This ﬁgure is available in black and white in print and in color at Glycobiology online.
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N-terminus, followed by a cytoplasmic domain and another two
hydrophobic segments at the C-terminus, which were proposed to
strongly contribute to its association to the ER membrane (Kämpf
et al. 2009). Our attempts to express and purify yeast Alg2, which
included transient transfection in human cells and baculovirus-
driven expression in insect cells, were unsuccessful. We then focused
on the human Alg2 homolog, which in contrast to the yeast protein
contains a single transmembrane helix and a cytoplasmic domain
(Supplementary Figure 1). Several parameters for the recombinant
expression of full length human Alg2 in HEK293 cells were opti-
mized, including the location of the afﬁnity tags tested and the
choice of detergent used to solubilize and purify the protein.
Screening was aided by the use of ﬂuorescence size exclusion chro-
matography (Supplementary Figure 2). We obtained best results
with an Alg2 construct containing a His10-YFP-3c tag fused to its
N-terminus. SDS–PAGE analysis showed that the produced protein
was pure (Figure 1B). A second band at higher mass was identiﬁed
by MS analysis as an impurity, but this contaminant did not affect
the catalytic activity of Alg2.
Chemo-enzymatic synthesis of GlcNAc2Man5
LLO analogs
The preparation of GlcNAc2Man5 LLO analogs using the puriﬁed
Alg proteins was pursued starting from synthetic LLO analogs that
contained a chitobiose moiety coupled to polyprenyl tails of differ-
ent length, which had been characterized by MS and nuclear mag-
netic resonance analyses previously (Figure 2 and Ramírez et al.
2017). We indirectly analyzed the addition of mannose units using
the generated LLO analogs as donor substrates for transfer onto
ﬂuorescently labeled peptides using puriﬁed single-subunit oligosac-
charyltransferase TbSTT3A (Ramírez et al. 2017). The resulting gly-
copeptides were then analyzed by SDS–PAGE tricine gels and by
liquid chromatography–tandem mass spectrometry (LC–MS/MS) to
identify the glycans attached to them (Figure 2A).
Addition of the ﬁrst mannose moiety using puriﬁed Alg1cyto was
successful with all four LLO analogs tested. A shift to higher mass
was observed in SDS–PAGE tricine gels for the glycopeptide carry-
ing the additional mannose unit, compared to glycopeptide that
only contained chitobiose (Figure 2B). LC–MS/MS analysis con-
ﬁrmed only one product after glycosylation of the peptide with the
LLOs originated from the reaction with Alg1, with a molecular
weight that corresponds to the peptide linked to GlcNAc2Man
(Figure 3 and Table I). The result was identical for the four polypre-
nyl tails tested.
The addition of the next two mannoses by Alg2 was successful
only with LLO analogs carrying the longer polyprenyl tails (3, C20
and 4, C25). For the LLO analogs with shorter lipid tails (1, C10 and
2, C15), the reaction with Alg2 was not complete (Figure 2B). LC–
MS/MS analyses of the glycopeptides originated from LLOs pro-
duced by Alg2, allowed us to identify the reaction products for each
LLO analog (Table I). For LLO 1, two different glycopeptides were
identiﬁed. The most abundant corresponded to peptide linked to the
GlcNAc2Man, according to its molecular weight. The second glyco-
peptide, for which only a small amount was detected, had a molecu-
lar weight coinciding with linked GlcNAc2Man2, originated from the
addition of the ﬁrst mannose to the LLO by Alg2 (Supplementary
Figure 2 and Table I). For LLO analog 2, glycopeptide containing
GlcNAc2Man3 was the main product, but a signiﬁcant amount of
peptide linked to GlcNAc2Man2 was also identiﬁed (Table I and
Supplementary Figure 3). Contrary to Alg1, Alg2 thus displays a
minimum length requirement for the lipid tail of the substrate LLO
in order to efﬁciently add both mannoses in vitro. This requirement
may be more pronounced for the addition of the α-1,3 mannose,
which occurs ﬁrst and may be the rate-determining step of the double
mannosylation reaction.
In order to assess if the α,1–6 branching glycosidic linkage was
generated by Alg2, we performed an α,1-2,3 mannosidase digestion
of the Man3-containing glycopeptides and analyzed the products by
high performance liquid chromatography (HPLC)-MS/MS. We iden-
tiﬁed Man2GlcNAc2 linked to peptide as the only product. A separ-
ate digestion combining α,1-2,3 and α,1–6 mannosidases led to
peptide linked to ManGlcNAc2, which agreed with the formation of
and α,1–6 glycosidic bond by Alg2 (Supplementary Figure 4).
The addition of the last two mannoses by Alg11Cyto was per-
formed only for the LLO analogs 3 and 4 (C20 and C25, respect-
ively), as shown in Figure 2B. LC–MS/MS analysis showed that the
Alg11-catalyzed reaction(s) were highly efﬁcient, as no signiﬁcant
amounts of unreacted substrates or side products were observed
(Figure 3 and Supplementary Figure 5), and the molecular weight of
the products coincided to peptide linked to GlcNAc2Man5 (Table I).
Kinetic characterization of the GlcNAc2Man5 LLO
analogs with TbSTT3A
We have earlier described the puriﬁcation and kinetic characteriza-
tion of the single-subunit oligosaccharyltransferase TbSTT3A using
LLO analogs containing the polyprenyl tails 3 and 4 and a chito-
biose glycan moiety (Ramírez et al. 2017). In vivo, TbSTT3A has
been observed to show a preference for Dol-PP-GlcNAc2Man5 over
Dol-PP-GlcNAc2Man9. We now evaluated if the addition of ﬁve
mannose units to the glycan moiety of the LLO analogs would affect
the in vitro activity of TbSTT3A. We analyzed the kinetics of the
N-glycosylation reactions using LLO analogs containing one, three
or ﬁve Mannose units coupled to the polyprenyl tails 3 and 4. As
shown in Figure 4, the LLO-TbSTT3A afﬁnities (analyzed by KM
values) and the glycosylation efﬁciencies (reﬂected in kcat values) did
not alter signiﬁcantly for the tested LLO analogs (Table II), indicat-
ing that the additional mannose units in the glycan moiety of the
LLOs do not affect the in vitro binding to the OST enzyme nor the
catalytic step of the glycan transfer reaction.
Discussion
Dol-PP-GlcNAc2Man5 is an important intermediate LLO in eukary-
otic N-glycosylation, because it is the ﬁnal product of the cytoplas-
mic part of the biosynthesis and is ﬂipped to the ER lumen for
additional glycan transfer. In vitro characterization of proteins
involved in the biosynthesis of eukaryotic LLOs has been mostly
performed using the native substrates containing the lipid carrier
dolichol. Several studies which allowed the identiﬁcation and char-
acterization of Alg1 (Couto et al. 1984), Alg2 (Yamazaki et al.
1998; O’Reilly et al. 2006; Kämpf et al. 2009) and Alg11 (Cipollo
et al. 2001; Absmanner et al. 2010) required the extraction of native
substrates and/or products from yeast cells. Even though this
approach was proven successful for initial functional studies, it is
impractical for structural and detailed kinetic analyses, which
require higher solubility and purity as well as larger amounts of sub-
strates. We therefore devised a strategy to generate GlcNAc2Man5
LLO analogs that could be produced in large amounts and higher
purity. The ﬁrst mannosylation of the synthetic LLO analogs was
performed by incubation with the puriﬁed cytoplasmic domain of
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Alg1, which allowed us to use a single puriﬁcation step to have
highly pure LLO analogs that can be further used for biochemical
studies of the reactions involved in the biosynthesis of eukaryotic
LLO. Previous reports have shown that an LLO analog containing
phytanol coupled to chitobiose could be mannosylated by cell
extracts expressing Alg1 or by microsomal fractions from yeast or
pig liver (Flitsch et al. 1992; Revers et al. 1994; Wilson et al. 1995).
Additionally, the kinetic characterization of the β-1,4 manosyltrans-
ferase activity of recombinantly expressed and puriﬁed cytoplasmic
domain of Alg1 was recently reported (Li et al. 2017). Phytanol is
Fig. 3. LC–MS/MS analysis of the glycopeptides generated with the LLO analogs containing glycan moieties of increasing size following processing with Alg pro-
teins. For all reactions, the lipid tail 3 was used. Shown are the MS spectra for the glycopeptides containing chitobiose (A) and the products of the sequential
addition of mannose residues by Alg1Cyto (B), Alg2 (C) and Alg11Cyto (D). This ﬁgure is available in black and white in print and in color at Glycobiology online.
Table I. LC–MS/MS analysis of the glycopeptides generated with the LLOs produced by Alg proteins.
LLO analog Alg reaction Observed m/z Glycan attached
Citronellyl-PP-Chitobiose (1) Alg1 1022.872+ GlcNAc2Man
Alg2 1022.872+ GlcNAc2Man
1103.902+ GlcNAc2Man2
Farnesyl-PP-Chitobiose (2) Alg1 1022.872+ GlcNAc2Man
Alg2 1103.902+ GlcNAc2Man2
1184.932+ GlcNAc2Man3
NerylCitronellyl-PP-Chitobiose (3) Alg1 1022.872+ GlcNAc2Man
Alg2 1184.932+ GlcNAc2Man3
790.293+ GlcNAc2Man3
Alg11 1346.982+ GlcNAc2Man5
898.323+ GlcNAc2Man5
FarnesylCitronellyl-PP-Chitobiose (4) Alg1 1022.872+ GlcNAc2Man
Alg2 1184.932+ GlcNAc2Man3
790.293+ GlcNAc2Man3
Alg11 1346.982+ GlcNAc2Man5
898.323+ GlcNAc2Man5
LC–MS/MS, liquid chromatography–tandem mass spectrometry; LLO, lipid-linked oligosaccharide.
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composed of four saturated isoprenyl units, whereas the lipid car-
riers we used here have different masses and double bond stereo-
chemistry, showing that the lipid part of the LLO does not have an
critical role in the Alg1-catalyzed reaction. There are no biochemical
studies of puriﬁed Alg2 reported, and all the insight into its activity
is derived from studies performed in vivo or with membrane frac-
tions containing Alg2 (Flitsch et al. 1992; Yamazaki et al. 1998;
O’Reilly et al. 2006; Kämpf et al. 2009). Our results showed for the
ﬁrst time the activity of puriﬁed Alg2 with LLO analogs carrying
shorter lipid tails than dolichol. Previously, it was reported that
microsome fractions from yeast or pig liver could produce a LLO
GlcNAc2Man3 analog using phytanol-PP-GlcNAc2 as substrate. We
found that Alg2 was only active in LLOs carrying the longest oligo-
prenyl tails (C20 and C25), showing that the length of the lipid car-
rier but not the oxidation state of the lipid moiety was important for
the correct function of Alg2 in vitro. This suggests functionally rele-
vant interactions of the lipid tail with the membrane-embedded part
of the protein. However, it was shown that truncations of Alg2 are
catalytically active in vivo as long as the protein is still associated to
the ER membrane by either its N-terminal or C-terminal domain
(Kämpf et al. 2009), suggesting that the interaction in the membrane
with the LLO substrate is not highly speciﬁc. The puriﬁcation we
developed for Alg2 provides an opportunity for future mechanistic
studies of the remarkable dual activity of the glycosyltransferase in
generating distinct glycosidic linkages.
The two manosylation steps to generate GlcNAc2Man5 LLO
analogs were performed by the puriﬁed cytoplasmic domain of
Alg11. Similar to Alg1, it had been shown that the N-terminal trans-
membrane helix of Alg11 is not required for the function of the pro-
tein in vivo (Absmanner et al. 2010). Similarly to Alg2, the
biochemical characterization of Alg11 had been only performed
using the native substrate Dol-PP-GlcNAc2Man3 (Cipollo et al.
2001; O’Reilly et al. 2006). We now show catalytic activity of
Alg11 on LLO analogs with shorter lipid tails.
The LLO analogs we produced accurately represented the differ-
ent glycan intermediates in eukaryotic LLO biosynthesis and offer
advantages for future mechanistic and structural studies, due to the
solubility and amounts that can be generated. Specially, analogs of
Dol-PP-GlcNAc2Man5 are of great interest because they can be used as
substrates for biochemical studies of at least three different proteins: the
ﬂippase that translocates Dol-PP-GlcNAc2Man5 to the ER lumen, the
Alg3 protein that adds the sixth mannose unit in the ER lumen, as well
as oligosaccharyltransferases including the single-subunit TbSTT3A
(Izquierdo et al. 2009, 2012). Given the in vivo preference of TbSTT3A
for Dol-PP-GlcNAc2Man5 over Dol-PP-GlcNAc2Man9, it was remark-
able that our biochemical characterization of TbSTT3A showed no
effect of the glycan length on the apparent afﬁnity of the LLOs. This
suggests no speciﬁc contact or interaction of these glycan moieties with
TbSTT3A. This is analogous to observations obtained with the bacterial
oligosaccharyltransferase PglB, where no signiﬁcant differences were
observed in the in vitro activity with the native Und-PP-BacGalNAc5Glc
or its intermediate Und-PP-BacGalNAc2 (Lizak et al. 2014).
Our chemo-enzymatic approach to produce GlcNAc2Man5 LLO
analogs containing lipid carriers with four and ﬁve isoprenyl units
will not only allow mechanistic and structural studies of the enzymes
that use GlcNAc2Man5 LLOs as substrates, but also represents a
ﬁrst step at exploiting the puriﬁed components for the generation of
glycoproteins in vitro.
Materials and methods
Cloning, expression and puriﬁcation of Alg1Cyto, Alg2
and Alg11Cyto
The gene fragments encoding the cytoplasmic domain of Alg1 (aa
33–349) and Alg11 (aa 46–548) were ampliﬁed by PCR using as
template previously reported plasmids containing the ALG1
(Shimma et al. 1997) and ALG11 (Helenius et al. 2002) genes from
Saccharomyces cerevisiae, and cloned into a pQE80 (Qiagen,
Hilden, Germany) derivative carrying a His10-zz-TEV tag at the
N-terminus. The gene encoding human Alg2 was ampliﬁed using
Fig. 4. Kinetic analysis of LLO analogs containing polyprenyl tails (3) and (4).
Glycosylation experiments were performed with 20 nM TbSTT3A protein,
5 μM peptide 5CF-GSDANYTYTQ, 10mM MnCl2, 150mM NaCl, 20mM Hepes
pH 7.5, 0.035% N-dodecyl-β-D-maltopyranoside (DDM), 0.007% Cholesteryl
Hemisuccinate Tris Salt (CHS) and different concentrations of synthetic LLO
analogs. Data points reﬂect the mean of three separate measurements. Error
bars indicate standard deviations. Data were ﬁtted by nonlinear regression
according to the Michaelis–Menten formula using PRISM. This ﬁgure is avail-
able in black and white in print and in color at Glycobiology online.
Table II. Kinetic analysis of TbSTT3A with the different LLO
analogs
LLO analog KM (μM) kcat (pep/min)
(3)-PP-GlcNAc2 2.7 ± 0.4 10.6 ± 0.4
(3)-PP-GlcNAc2Man 8.8 ± 1.2 16.7 ± 1.3
(3)-PP-GlcNAc2Man3 10.8 ± 1.6 17.6 ± 1.2
(3)-PP-GlcNAc2Man5 3.3 ± 0.8 12.1 ± 0.8
(4)-PP-GlcNAc2 3.7 ± 0.9 10.6 ± 0.7
(4)-PP-GlcNAc2Man 7.7 ± 1.6 17.0 ± 1.4
(4)-PP-GlcNAc2Man3 18.8 ± 5.0 18.1 ± 2.8
(4)-PP-GlcNAc2Man5 7.1 ± 1.5 12.9 ± 1.1
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cDNA from HEK293 cells as template, and cloned into a modiﬁed
pUC57 vector carrying His10-YFP tag at the N-terminus.
Alg1Cyto and Alg11Cyto were overexpressed in E. coli BL21-Gold
(DE3) (Stratagene, San Diego, CA) strain. Cells were grown at 37°C
in Luria Bertani medium to A600 nm of 1.0, before expression was
induced by the addition of 0.5mM isopropyl β-D-1-thiogalactopyra-
noside, for 16 h at 18°C. All following steps were performed at 4°C.
Cells were collected by centrifugation, resuspended in lysis buffer
(20mM Tris–HCl, pH 7.5; 150mM NaCl; 5mM β-mercaptoethanol;
0.5mM phenyl- methanesulfonylﬂuoride) and disrupted by ﬁve cycles
of sonication (50% amplitude and 50% duty cycle), the cell lysate
was incubated with a ﬁnal concentration of 0.5% Triton X-100, for
1 h. Cell debris and insoluble material were pelleted by ultracentrifu-
gation at 35,000 rpm, in Ti45i rotor, for 30min. The supernatant was
supplemented with 25mM imidazole and loaded onto a NiNTA
superﬂow afﬁnity column (Qiagen, Hilden, Germany), washed exten-
sively with the same lysis buffer but containing 50mM imidazole and
0.05% Triton X-100. Elution was performed in the same buffer but
containing 200mM imidazole. The proteins were desalted into
20mM Tris–HCl, pH7.5; 150mM NaCl; 5mM β-mercaptoethanol
and 0.05% Triton X-100 using a HiPrep 26/10 column (GE
Healthcare, Little Chalfont, UK).
Expression of Alg2 was performed by transient transfection in
human embryonic kidney cells (HEK293), using branched PEI as trans-
fection agent in a 2:1 (w/w) PEI:DNA ratio. After transfection, cells were
incubated at 37°C, for 48 h, followed by harvesting and washing with
phosphate-buffered saline. Cell pellets were frozen in liquid nitrogen and
stored at –80°C until the time of use. For puriﬁcation, cell pellets were
thawed and resuspended in lysis buffer (50mM Hepes, pH 7.5;
250mM NaCl; 10% (w/v) glycerol) supplemented with cOmplete™,
EDTA-free Protease Inhibitor Cocktail (Roche, Basel, Switzerland).
Lysis was performed by dounce homogenization on ice and the cell
lysate was incubated with 1% N-dodecyl-β-D-maltopyranoside (w/v)
(DDM, Anatrace), 0.1% Cholesteryl Hemisuccinate Tris Salt (w/v)
(CHS, Anatrace) for two hours at 4°C, then submitted to high-speed
centrifugation (35,000 rpm, Ti45i rotor, 30min). All subsequent buffers
contained 0.02% (w/v) DDM, 0.002% (w/v) CHS. The supernatant
was loaded onto a Ni/NTA superﬂow afﬁnity column (Qiagen, Hilden,
Germany), washed with the same lysis buffer but containing 50mM
imidazole and eluted with the same buffer but containing 200mM imid-
azole. The protein was desalted into 20mM Hepes, pH7.5; 150mM
NaCl; 5mM β-mercaptoethanol, 0.02%DDMand 0.002%CHS, using
aHiPrep 26/10 column (GEHealthcare, Little Chalfont, UK).
Chemo-enzymatic synthesis of GlcNAc2Man5
LLO analogs
The chemical synthesis of the LLO analogs (S)-Citronellyl-PP-chito-
biose, Farnesyl-PP-chitobiose, (S)-NerylCitronellyl-PP-chitobiose
and (S)-FarnesylCitronellyl-PP-Chitobiose was previously described
in detail (Ramírez et al. 2017). All the manosylation reactions were
performed in the following buffer (20mM Tris–HCl, pH 7.5;
150mM NaCl; 10 mM MgCl2; 5 mM β-Mercaptoethanol and 0.5%
Triton X-100). The concentration of the LLO analogs used was in
the range of 500 μM to 2mM.
For the ﬁrst mannosylation with Alg1Cyto, the concentration of
GDP-Mannose was adjusted to 2:1 molar ratio (GDP-Man:LLO),
and the reaction was incubated at 37°C for 1 h. For the reactions
with Alg2 and Alg11Cyto the concentration of GDP-Mannose was
adjusted to 4:1 molar ratio (GDP-Man:LLO), and the reactions
were incubated over night at 25°C.
The puriﬁcation of the reaction products was performed by
freeze drying of the reaction mixture followed by CHCl3:MeOH
(2:1, v/v) extraction. The organic phase was dried in a nitrogen
stream and the LLO products resuspended in the reaction buffer or
water according to the next step.
The concentration of the different LLO analogs after puriﬁcation
was determined by titrating different amounts of LLOs against a
constant amount of the ﬂuorescently labeled acceptor peptide 5CF-
GSDANYTYTQ in an in vitro glycosylation assay with TbSTT3A.
Mannosidase digestion of glycopeptides
Digestion of glycopeptides with α,1-2,3 and α,1–6 (NEB, Ipswich,
MA) was performed following manufacturer’s instructions. The pro-
ducts were analyzed by tricine SDS–PAGE and liquid chromatog-
raphy mass spectrometry.
In vitro glycosylation assays with TbSTT3A
TbSTT3A was puriﬁed as described previously (Ramírez et al.
2017). Reaction mixtures contained 20nM puriﬁed TbSTT3A,
10mM MnCl2, 150mM NaCl, 20mM Hepes pH 7.5, 0.035%
DDM, 0.007% CHS, 5 μM of the ﬂuorescently labeled acceptor
peptide 5CF-GSDANYTYTQ and were incubated with different
concentrations of LLO analogs (1–20 μM) for 10min. Reactions
were stopped by the addition of 4X SDS Laemmli buffer and sam-
ples were diluted 200-fold prior to analysis by Tricine SDS–PAGE
(Schägger 2006). Fluorescent bands for peptide and glycopeptide
were visualized by using a Typhoon Trio Plus imager (GE
Healthcare, Little Chalfont, UK) with excitation set at 488 nm and
using a 526 nm SP emission ﬁlter. The amount of formed glycopep-
tide was determined from band intensities of ﬂuorescence gel scans
(ImageJ) (Gerber et al. 2013). Data were ﬁtted by nonlinear regres-
sion according to the Michaelis-Menten formula using PRISM
software.
Identiﬁcation of glycopeptides by mass spectrometry
Samples were analyzed on a calibrated Q Exactive mass spectrom-
eter (Thermo Fischer Scientiﬁc, Bremen, Germany) coupled to an
Thermo Dionex Ultimate 3000 UHPLC system (Thermo Fischer
Scientiﬁc, Waltham, MA). Kinetex XB-C18 column, 150 × 2.1 mm
ID, and 2.6 μm particle size column (Phenomenex, Torrance, CA)
were used as the stationary phase. LC mobile phase was composed
of two buffer solutions: buffer A was 100% deionized water with
0.1% formic acid (FA) and buffer B was 100% acetonitrile with
0.1% FA. The samples were eluted with a ﬂow rate of 0.3mL/min
by a gradient from 10% to 98% of B in 10min and back to 10% B
in 3min. The column oven was set to 50°C. Both LC and MS were
controlled by XCalibur 2.2 SP1. Data-dependence acquisition
(DDA) was ﬁrst applied to characterize each compound and its cor-
responding converted product. One scan cycle comprised of a full-
scan MS survey spectrum, followed by up to 5 sequential HCD MS/
MS with the consideration of theoretical molecular weight of each
compound and its corresponding converted product and intense sig-
nals above a threshold of 50,000. Both full-scan MS HCD
(700–2300m/z) and MS/MS spectra were acquired in the FT-
Orbitrap at a resolution of 70,000 at 400m/z for full MS scan and
17,500 for MS/MS scan. HCD was performed by stepped collision
energy at 30 V. AGC target values were 3e6 for full FTMS scans
and 1e5 for HCD MS/MS scans. Data analysis was performed by
XCalibur 3.0 Qual Browser.
732 AS Ramírez et al.
Downloaded from https://academic.oup.com/glycob/article-abstract/27/8/726/3859201
by Universitaetsbibliothek Bern user
on 18 December 2017
Supplementary data
Supplementary data is available at Glycobiology online.
Funding
This work was supported by the Swiss National Science Foundation
(Transglyco Sinergia program to M.A., J.-L.R. and K.P.L.).
Acknowledgments
We thank the Mass Spectrometry Service (Department of Chemistry and
Biochemistry, University of Berne) for recording MS spectra of synthetic
substrates.
Conﬂict of interest statement
None declared.
Abbreviations
CHS, Cholesteryl Hemisuccinate Tris Salt; DDM, N-dodecyl-β-D-maltopyra-
noside; ER, endoplasmic reticulum; FA, formic acid; HPLC, high performance
liquid chromatography; LC–MS/MS, liquid chromatography–tandem mass
spectrometry; LLO, lipid linked oligosaccharide; MS, mass spectrometry;
SDS–PAGE, sodium dodecyl sulphate–polyacrylamide gel electrophoresis.
References
Absmanner B, Schmeiser V, Kämpf M, Lehle L. 2010. Biochemical character-
ization, membrane association and identiﬁcation of amino acids essential
for the function of Alg11 from Saccharomyces cerevisiae, an alpha1,2-
mannosyltransferase catalysing two sequential glycosylation steps in the
formation of the l. Biochem J. 426:205–217.
Aebi M. 2013. N-linked protein glycosylation in the ER. Biochim Biophys
Acta. 1833:2430–2437.
Breitling J, Aebi M. 2013. N-linked protein glycosylation in the endoplasmic
reticulum. Cold Spring Harb Perspect Biol. 5:a013359–a013359.
Burda P, Aebi M. 1999. The dolichol pathway of N-linked glycosylation.
Biochim Biophys Acta. 1426:239–257.
Cipollo JF, Trimble RB, Chi JH, Yan Q, Dean N. 2001. The yeast ALG11
gene speciﬁes addition of the terminal α1,2-Man to the Man5GlcNAc2-
PP-dolichol N-glycosylation intermediate formed on the cytosolic side of
the endoplasmic reticulum. J Biol Chem. 276:21828–21840.
Couto JR, Huffaker TC, Robbins PW. 1984. Cloning and expression in
Escherichia coli of a yeast mannosyltransferase from the asparagine-
linked glycosylation pathway. J Biol Chem. 259:378–382.
Dell A, Galadari A, Sastre F, Hitchen P. 2010. Similarities and differences in
the glycosylation mechanisms in prokaryotes and eukaryotes. Int J
Microbiol. 2010:148178.
Flitsch SL, Heather Pinches VAL, Taylor JP, Turner NJ. 1992. Chemo-
enzymatic Synthesis of a Lipid-linked Core Trisaccharide of N-Linked
Glycoproteins. J Chem Soc Perkin Trans. 1:2087–2093.
Gao X-D, Moriyama S, Miura N, Dean N, Nishimura S-I. 2008. Interaction
between the C termini of Alg13 and Alg14 mediates formation of the
active UDP-N-acetylglucosamine transferase complex. J Biol Chem. 283:
32534–32541.
Gao X-D, Nishikawa A, Dean N. 2004. Physical interactions between the
Alg1, Alg2, and Alg11 mannosyltransferases of the endoplasmic reticu-
lum. Glycobiology. 14:559–570.
Gerber S, Lizak C, Michaud G, Bucher M, Darbre T, Aebi M, Reymond J-L,
Locher KP. 2013. Mechanism of bacterial oligosaccharyltransferase:
in vitro quantiﬁcation of sequon binding and catalysis. J Biol Chem. 288:
8849–8861.
Helenius J, Ng DTW, Marolda CL, Walter P, Valvano MA, Aebi M. 2002.
Translocation of lipid-linked oligosaccharides across the ER membrane
requires Rft1 protein. Nature. 415:447–450.
Izquierdo L, Mehlert A, Ferguson MA. 2012. The lipid-linked oligosaccharide
donor speciﬁcities of Trypanosoma brucei oligosaccharyltransferases.
Glycobiology. 22:696–703.
Izquierdo L, Schulz BL, Rodrigues JA, Lucia Güther MS, Procter JB, Barton
GJ, Aebi M, Ferguson MA. 2009. Distinct donor and acceptor speciﬁci-
ties of Trypanosoma brucei oligosaccharyltransferases. EMBO J. 28:
2650–2661.
Jarrell KF, Ding Y, Meyer BH, Albers S-V, Kaminski L, Eichler J. 2014.
N-linked glycosylation in Archaea: a structural, functional, and genetic
analysis. Microbiol Mol Biol Rev. 78:304–341.
Kämpf M, Absmanner B, Schwarz M, Lehle L. 2009. Biochemical character-
ization and membrane topology of Alg2 from Saccharomyces cerevisiae
as a bifunctional α1,3- and 1,6-mannosyltransferase involved in lipid-
linked oligosaccharide biosynthesis. J Biol Chem. 284:11900–11912.
Kukuruzinska MA, Apekin V, Lamkin MS, Hiltz A, Rodriguez A, Lin CC,
Paz MA, Oppenheim FG. 1994. Antisense RNA to the ﬁrst N-
glycosylation gene, ALG7, inhibits protein N-glycosylation and secretion
by xenopus oocytes. Biochem Biophys Res Commun. 198:1248–1254.
Li S-T, Wang N, Xu S, Yin J, Nakanishi H, Dean N, Gao X-D. 2017.
Quantitative study of yeast Alg1 beta-1, 4 mannosyltransferase activity, a
key enzyme involved in protein N-glycosylation. Biochim Biophys Acta.
1861:2934–2941.
Lizak C, Gerber S, Zinne D, Michaud G, Schubert M, Chen F, Bucher M,
Darbre T, Zenobi R, Reymond J-L et al. 2014. A catalytically essential
motif in external loop 5 of the bacterial oligosaccharyltransferase PglB.
J Biol Chem. 289:735–746.
Lu J, Takahashi T, Ohoka A, Nakajima K-I, Hashimoto R, Miura N,
Tachikawa H, Gao X-D. 2012. Alg14 organizes the formation of a multi-
glycosyltransferase complex involved in initiation of lipid-linked oligosac-
charide biosynthesis. Glycobiology. 22:504–516.
Manthri S, Güther MLS, Izquierdo L, Acosta-serrano A, Ferguson MAJ.
2008. Deletion of the TbALG3 gene demonstrates site-speciﬁc N-glycosy-
lation and N-glycan processing in Trypanosoma brucei. Glycobiology.
18:367–383.
Nothaft H, Szymanski CM. 2010. Protein glycosylation in bacteria: sweeter
than ever. Nat Rev Microbiol. 8:765–778.
O’Reilly MK, Zhang G, Imperiali B. 2006. In vitro evidence for the dual func-
tion of Alg2 and Alg11: essential mannosyltransferases in N-linked glyco-
protein biosynthesis. Biochemistry. 45:9593–9603.
Ramírez AS, Boilevin J, Biswas R, Gan BH, Janser D, Aebi M, Darbre T,
Reymond J-L, Locher KP. 2017. Characterization of the single-subunit
oligosaccharyltransferase STT3A from Trypanosoma brucei using syn-
thetic peptides and lipid-linked oligosaccharide analogs. Glycobiology.
27:525–535.
Revers L, Wilson BH, Webberley MC, Flitsch SL. 1994. The potential doli-
chol recognition sequence of f-1,4-mannosyltransferase not required for
enzymic activity using phytanyl-pyrophosphoryl-a-N,N’-diacetylchitobio-
side as acceptor. Biochem J. 299:23–27.
Schägger H. 2006. Tricine–SDS-PAGE. Nat Protoc. 1:16–22.
Shimma A, Nishikawa B, bin Kassim Y, Nishikawa A, Kassim B, bin, Eto A,
Jigami Y. 1997. A defect in GTP synthesis affects mannose outer chain
elongation in Saccharomyces cerevisiae. Mol Gen Genet MGG. 256:
469–480.
Takeuchi K, Yamazaki H, Shiraishi N. 1999. Characterization of an alg2
mutant of the zygomycete fungus Rhizomucor pusillus. Biochim Biophys
Acta. 9:1287–1293.
Wilson IB, Webberley MC, Revers L, Flitsch SL. 1995. Dolichol is not a
necessary moiety for lipid-linked oligosaccharide substrates of the manno-
syltransferases involved in in vitro N-linked-oligosaccharide assembly.
Biochem J. 310(Pt 3):909–916.
Yamazaki H, Shiraishi N, Takeuchi K, Ohnishi Y, Horinouchi S. 1998.
Characterization of alg2 encoding a mannosyltransferase in the zygomy-
cete fungus Rhizomucor pusillus. Gene. 221:179–184.
733Chemo-enzymatic synthesis of lipid-linked GlcNAc2Man5 oligosaccharides
Downloaded from https://academic.oup.com/glycob/article-abstract/27/8/726/3859201
by Universitaetsbibliothek Bern user
on 18 December 2017
